
Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
Diagnostic Testing and Emerging Technologies
LAB COMPLIANCE ADVISOR
LABORATORY INDUSTRY REPORT
NATIONAL LAB REPORTER
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
Enzo recently announced that it is selling its lab division to LabCorp for $146 million in cash.
A recently released report estimates that the US market will grow at a CAGR of 4.2 percent over the next seven years.
Specially crafted lab tests speed up adoption of novel drug treatments.
Cost cutting and restructuring has become the order of the day for many lab companies.